Effectiveness of anti-resorption therapies of postmenopausal osteoporosis;Účinnost antiresorpční léčby postmenopauzální osteoporózy

Vnitrni Lekarstvi

Volumn 53, Issue 3, 2007, Pages 293-299

  Štěpán, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biochemical markers; BMD; Fracture; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; DRUG EFFICACY; DRUG SAFETY; FRACTURE; HEREDITY; HUMAN; INCIDENCE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; REVIEW; RISK FACTOR; FEMALE;

BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 34247236185     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795.
2. Kado DM, Duong T, Stone KL et al. Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos Int 2003; 14: 589-594.
3. Štěpán J, Payer J, Abrahámová J. Stratifikace léčby postmenopauzální osteoporózy. Prakt Lék 2004; 84: 500-506.
4. Lufkin EG, Whitaker MD, Nickelsen T et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13: 1747-1754.
5. Maricic M, Adachi JD, Sarkar S et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162: 1140-1143.
6. Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461-468.
7. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91.
8. Cranney A, Guyatt G, Griffith L et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-578.
9. Kado DM, Browner WS, Palermo L et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159: 1215-1220.
10. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323.
11. Štěpán J, Šmíd M, Prokeš M et al. Ekonomicke aspekty osteoporozy. Čas Lék Česko 1998; 137: 707-715.
12. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
13. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-2082.
14. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-340.
15. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344-1352.
16. Štěpán JJ: Algoritmus diagnostiky a léčby osteoporózy. Farmakoterapie 2005; 1: 485-494.
17. Cummings SR, Palermo L, Browner W et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 2000; 283: 1318-1321.
18. Štěpán JJ, Zikán V. Calcitonin load test to assess the efficacy of salmon calcitonin. Clin Chim Acta 2003; 336: 49-55.
19. Hochberg MC, Ross PD, Black D et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999; 42: 1246-1254.
20. Štěpán J. Kvalita kosti: které účinky léčby můžeme monitorovat a co to předpokládá? Osteologicky Bull 2003; 8: 75-81.
21. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000; 11: 55-65.
22. Gerdhem P, Ivaska KK, Alatalo SL et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004; 19: 386-393.
23. Borah B, Dufresne TE, Chmielewski PA et al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004; 34: 736-746.
24. Delmas PD, Genant HK, Crans GG et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522-532.
25. Roy DK, Pye SR, Lunt M et al. Falls explain between-center differences in the incidence of limb fracture across Europe. Bone 2002; 31: 712-717.
26. Dukas L, Schacht E, Stahelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos Int 2005; 16: 1683-1690.
27. Cramer JA, Amonkar MM, Hebborn A et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460.
28. Turbi C, Herrero Beaumont G et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26: 245-256.
29. Martino S, Cauley JA, Barrett Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in post menopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761.
30. Richer E, Lewis MA, Odvina CV et al. Reduction in normalized bone elasticity following long-term bisphosphonate treatment as measured by ultrasound critical angle reflectometry. Osteoporos Int 2005; 16: 1384-1392.
31. Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-1301.
32. Štěpán JJ, Burr DB, Pavo I et al. Prevalent fractures, low bone mineral density and ageing are associated with greater histomorphometric indicators of microdamage accumulation in postmenopausal women. J Bone Miner Res 2005; 20: S90-91.
33. Caro JJ, Ishak KJ, Huybrechts KF et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003-1008.
34. Bone HG, Hosking D, Devogelaer JP et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-1199.
35. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 2001; 12: 385-390.
36. Michalská D, Štěpán JJ, Basson BR et al. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006; 91: 870-877.
37. Silva MJ, Gibson LJ. Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Bone 1997; 21: 191-199.
38. Ettinger B, San Martin J, Crans GG et al. Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously treated with an antiresorptive drug. J Bone Mineral Research 2003; 18: S15.
39. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-645.
40. Chesnut III CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249.
41. Chesnut CH, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109: 267-276.
42. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-468.
43. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-2822.
44. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443.
45. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-79.
46. McCloskey E, Selby P, Davies M et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004; 19: 728-736.